AU2022205937A1 - Combination therapies - Google Patents

Combination therapies Download PDF

Info

Publication number
AU2022205937A1
AU2022205937A1 AU2022205937A AU2022205937A AU2022205937A1 AU 2022205937 A1 AU2022205937 A1 AU 2022205937A1 AU 2022205937 A AU2022205937 A AU 2022205937A AU 2022205937 A AU2022205937 A AU 2022205937A AU 2022205937 A1 AU2022205937 A1 AU 2022205937A1
Authority
AU
Australia
Prior art keywords
formula
compound
salt
disease
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022205937A
Other languages
English (en)
Other versions
AU2022205937A9 (en
Inventor
Paul Chamberlin
Jaikrishna Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imbria Pharmaceuticals Inc
Original Assignee
Imbria Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imbria Pharmaceuticals Inc filed Critical Imbria Pharmaceuticals Inc
Publication of AU2022205937A1 publication Critical patent/AU2022205937A1/en
Publication of AU2022205937A9 publication Critical patent/AU2022205937A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2022205937A 2021-01-06 2022-01-05 Combination therapies Pending AU2022205937A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163134243P 2021-01-06 2021-01-06
US63/134,243 2021-01-06
US202163147801P 2021-02-10 2021-02-10
US63/147,801 2021-02-10
PCT/US2022/011336 WO2022150403A1 (en) 2021-01-06 2022-01-05 Combination therapies

Publications (2)

Publication Number Publication Date
AU2022205937A1 true AU2022205937A1 (en) 2023-07-13
AU2022205937A9 AU2022205937A9 (en) 2024-09-26

Family

ID=82358297

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022205937A Pending AU2022205937A1 (en) 2021-01-06 2022-01-05 Combination therapies

Country Status (8)

Country Link
US (1) US20240082242A1 (https=)
EP (1) EP4274436A4 (https=)
JP (1) JP2024501764A (https=)
KR (1) KR20230129250A (https=)
AU (1) AU2022205937A1 (https=)
CA (1) CA3206848A1 (https=)
IL (1) IL304054A (https=)
WO (1) WO2022150403A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3976101A4 (en) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION
EP4146215A4 (en) * 2020-05-04 2024-05-01 Imbria Pharmaceuticals, Inc. DOSAGE METHODS FOR TREATMENT OF CARDIOVASCULAR PROBLEMS
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100285A (en) * 1976-04-09 1978-07-11 Nippon Shinyaku Co., Ltd. N-substituted trialkoxybenzyl piperazine derivatives
IL283725B2 (en) * 2017-06-20 2024-04-01 Imbria Pharmaceuticals Inc Compositions and methods for increasing efficiency of cardiac metabolism
EP3866794B1 (en) * 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US20220168431A1 (en) * 2019-03-18 2022-06-02 Imbria Pharmaceuticals, Inc. Methods of treating cancer using trimetazidine-based compounds
US20210401833A1 (en) * 2020-06-30 2021-12-30 Imbria Pharmaceuticals, Inc. Modified release formulations of modified forms of trimetazidine

Also Published As

Publication number Publication date
CA3206848A1 (en) 2022-07-14
IL304054A (en) 2023-08-01
JP2024501764A (ja) 2024-01-15
US20240082242A1 (en) 2024-03-14
EP4274436A1 (en) 2023-11-15
AU2022205937A9 (en) 2024-09-26
WO2022150403A1 (en) 2022-07-14
EP4274436A4 (en) 2024-12-11
KR20230129250A (ko) 2023-09-07

Similar Documents

Publication Publication Date Title
US20240082242A1 (en) Combination therapies
Watt et al. Intravenous adenosine in the treatment of supraventricular tachycardia: a dose‐ranging study and interaction with dipyridamole.
TW518222B (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
JP6244497B1 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
US12502389B2 (en) Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
JP2011084583A (ja) 短時間型β遮断薬を有効成分とする心拍数減少剤
JP2019529491A (ja) 毛髪の成長を刺激するためのアルファ−ケトブチレート、アルファ−ケトグルタレート、および２−ヒドロキシブチレート
WO2020243120A1 (en) Methods of treating fibrosis using compounds that promote glucose oxidation
JP3253302B2 (ja) ３−ジアルキルアミノエトキシベンゾイル−ベンゾフランを含有する非経口溶液
JP2025015727A (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤
US20240374584A1 (en) Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine
US20070203091A1 (en) Methods and therapeutic compositions for improving liver, blood flow and skeletal muscle functions in advanced diseases and aging
CN116829000A (zh) 组合疗法
WO1999040919A1 (en) Remedies for cardiac dilastolic disorders
EP4171232A1 (en) Modified release formulations of modified forms of trimetazidine
EP4185291A1 (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
CA2566684C (en) Pharmaceutical nitrones
JP2010248263A (ja) 塩酸ランジオロールを含有する頻脈性不整脈の治療剤
UA101612C2 (uk) Застосування івабрадину у способі коронарографії шляхом багатошарової спіральної комп'ютерної томографії
JP4784037B2 (ja) 塩酸ランジオロールを含有する頻脈性不整脈の治療剤
JPH03291220A (ja) アスコクロリン誘導体を有効成分とするＣａ代謝異常改善剤
JP5648287B2 (ja) 冠動脈の描出能改善剤
HK40097424A (zh) 前列地尔脂质体预防和/或治疗肾损伤的用途

Legal Events

Date Code Title Description
SREP Specification republished